Johnson & Johnson offers $5.5 billion settlement to settle talc lawsuits

Healthcare and pharmaceutical giant Johnson & Johnson has proposed a massive financial agreement to resolve a staggering wave of litigation. According to Newson6, the company offered $5.5 billion to settle tens of thousands of lawsuits alleging that its baby powder and other talcum powder products caused ovarian cancer. The announcement marks a critical pivot in a legal saga that has shadowed the New Jersey-based enterprise for over a decade and a half, as reported by Econotimes.

The proposed settlement covers approximately 76,000 claims, representing nearly all remaining ovarian cancer cases currently consolidated in federal multidistrict litigation in New Jersey alongside related state court proceedings, according to CBS News. However, Ibtimes notes that the agreement specifically covers roughly 69,000 cases while accounting for 99.75% of remaining talc claims. Crucially, the agreement is strictly conditioned on the express participation of at least 95% of the remaining claimants.

Related imagery

Corporate leadership continues to contest the underlying science behind the claims. Erik Haas, the vice president of litigation for Johnson & Johnson, asserted in a public statement that the allegations lack scientific merit.

"While we are confident the Company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the Company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives,"

Erik Haas, Vice President of Litigation, via Newson6

The company maintains that extensive scientific research supports the safety of its cosmetic talc products, emphasizing that its talc never contained asbestos and does not cause cancer, as detailed by Econotimes.

Despite these denials, external bodies have shifted their stance on the ingredient. The World Health Organization classified talc as "probably carcinogenic to humans". Johnson & Johnson previously halted sales of its talc-based baby powder in the United States and Canada in 2020. The company also previously settled most cases alleging that its talcum powder contained traces of asbestos blamed for causing mesothelioma, according to CBS News.

The path to this proposed settlement diverged significantly from the company's prior legal strategies. Ibtimes reports that this agreement marks a new approach after two failed attempts to resolve the litigation through subsidiary bankruptcies. Courts rejected those previous bankruptcy filings after finding that the parent company possessed the financial capability to pay claims without protection. Moreover, the settlement talks were reportedly accelerated by a recent federal court ruling. A federal judge cast doubt on individual plaintiffs' ability to establish specific causation—the legal requirement to prove that talc directly caused an individual claimant's cancer—after plaintiffs withdrew their specific causation experts in two bellwether trials before the court required them to justify why claims should not be dismissed, according to Econotimes and Ibtimes.

Plaintiffs' legal representation welcomed the development after years of procedural battles. Chris Seeger, the plaintiffs' lead counsel, highlighted the prolonged nature of the disputes.

"ensures ... (that the) plaintiffs receive fair and meaningful compensation for their injures. More than a decade of protracted litigation and three failed bankruptcies has left tens of thousands of women and their families waiting far too long for relief,"

Chris Seeger, Plaintiffs' Lead Counsel, via Newson6

Not all ongoing legal disputes are resolved by this multi-billion-dollar proposal. Newson6 and Newsofbahrain report that the company faces a separate lawsuit in the United Kingdom over similar claims filed in 2025, where a law firm representing roughly 3,000 complainants estimates compensation claims to exceed £1 billion. Meanwhile, Ibtimes notes that the UK case covers more than 7,000 potential claimants, and the domestic settlement explicitly excludes separate mesothelioma claims, which the company intends to address separately.

Key Details of the Proposed Settlement

• Total proposed fund: $5.5 billion.
• Target scope: Approximately 76,000 ovarian cancer claims in federal multidistrict and state court proceedings.
• Participation threshold: Must be accepted by at least 95% of remaining eligible claimants to proceed.
• Payment schedule: An initial payment of up to $3 billion is expected in 2027, with no additional payments scheduled before 2028.
• Exclusions: Does not cover separate mesothelioma claims or ongoing litigation in the United Kingdom.

As Econotimes points out, investors will closely monitor whether enough claimants approve the proposal. If the strict threshold is not met, the agreement could unravel and leave the underlying litigation unresolved.